{"entity":{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","aka":[],"tldr":"Medical oncologist known for germ cell tumour research and anti-EGFR trials in colorectal cancer.","summary":"Carsten Bokemeyer is Director of the Department of Oncology, Hematology and BMT at Universitätsklinikum Hamburg-Eppendorf. A medical oncologist, his specialisms are testicular cancer, colorectal cancer and medical oncology. He led the OPUS trial of cetuximab with FOLFOX in colorectal cancer and has a long record in germ cell tumour research. His papers include a study of early tumour shrinkage as a predictor of long-term outcome in cetuximab-treated metastatic colorectal cancer, a European Urology report establishing serum microRNA miR-371a-3p as a biomarker for germ cell tumours, and a review of catumaxomab, a trifunctional anti-EpCAM antibody used for malignant ascites. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bokemeyer%20C%5BAuthor%5D%20cetuximab%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab"],"companies":[],"institutions":["uke-hamburg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Oncology, Hematology and BMT, UKE Hamburg","institutionId":"uke-hamburg","specialisms":["Testicular cancer","Colorectal cancer","Medical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bokemeyer%20C%5BAuthor%5D%20cetuximab%20colorectal"}],"papers":[{"title":"Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites","journal":"Expert Opinion on Biological Therapy","year":2010,"doi":"10.1517/14712598.2010.504706"},{"title":"Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours","journal":"European Urology","year":2017,"doi":"10.1016/j.eururo.2016.07.029"},{"title":"Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab","journal":"Journal of Clinical Oncology","year":2013,"doi":"10.1200/jco.2012.42.8532"}]},"route":"/people/carsten-bokemeyer/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"institution":[{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/"}]}}